Research at Pharmablock Sciences (Nanjing) Inc. has led to the development of spirooxindole compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors and thus reported to be useful for the treatment of viral infections.
A chance discovery has led to a new class of antibiotics with multiple arms that interacted with the cell wall of gram-positive bacteria, inhibiting their assembly and disarming them. “It was an accidental discovery. We were using it to stain cells. We also were running evaluations of antibiotics. One of my former students came to me and said: ‘I think we have discovered something that is quite potent as an antibiotic,’” the senior author Xingyu Jiang told BioWorld.
Merck Sharp & Dohme Corp. has disclosed pyrazolopyrimidine derivatives acting as DNA polymerase inhibitors reported to be useful for the treatment of herpes virus infection.
The protection against SARS-CoV-2 provided by spike-based vaccines, although effective, tends to decrease as the virus evolves and new variants of concern appear. Researchers from Osivax SAS reported the first results on cross-protection with OVX-033, a new human SARS-CoV-2 vaccine generated via the oligoDOM platform.
Researchers from Adiso Therapeutics Inc. have reported the discovery of a novel small-molecule dual NLRP1 and NLRP3 inflammasome inhibitor, ADS-032, being developed for the treatment of inflammatory diseases. Screening of an in-house bioactive compound library led to the discovery of ADS-032, a sulfonylurea compound.
The search for novel therapies that complement vaccine-induced immune protection against SARS-CoV-2 continues. In previous work, researchers at QIMR Berghofer Medical Research Institute and collaborators developed a cell-permeable and highly selective peptide called NACE2i, targeting nuclear angiotensin-converting enzyme 2 (ACE2). In particular, NACE2i spans and targets the ACE2 nuclear localization signal motif, successfully inhibiting nuclear translocation of ACE2 and viral replication in human cell lines infected with SARS-CoV-2.
Researchers from Central Drug Research Institute (CDRI) and Academy of Scientific & Innovative Research (AcSIR) have discovered novel antiplasmodial agents.
Aicuris Anti-infective Cures AG has announced its intention to focus on the development and commercialization of anti-infectives for immunocompromised individuals, and will discontinue research activities outside of this strategic scope.
RSS
